Indutrade AB (publ) (IDDWF) Q2 2026 Earnings Call Transcript

We had a good development in many areas in the quarter, starting with the top line development. Demand continued to improve and total order growth was 14%, of which 8% organically with the majority of our companies growing. Continued positive book-to-bill of 105%, and the strongest demand was with companies having customers within the medtech and pharma area and also the energy sector. Net sales increased 11% in total to a record high SEK 9 billion with strong organic growth of 5%. EBITA was also on a record high level and the EBITA margin improved to 14.7% with good operational leverage on the organic sales and margin accretive acquisitions. Cash flow from operating activities increased and inventory levels were flat from last year organically. We continued being successful in terms of acquisitions, 9 companies acquired in 2026 so far and slightly larger companies on average. Our pipeline remains strong. As mentioned, top line development was strong and demand improved, however, still varies across companies, geographies and segments. Companies with customers within medtech and